Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Business Wire•04/08/2026•16:00 ET
0
Whiz Insights
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
- Voucher to be used to accelerate review of a planned sNDA for plozasiran in severe hypertriglyceridemia
Get started
Create a free account to read the full story.